Botox for chronic migraine

Drug and Therapeutics Bulletin

Volumn 49, Issue 2, 2011, Pages 22-24

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; AZZALURE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOCOUTURE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANAPHYLAXIS; CHRONIC TENSION HEADACHE; CLOSTRIDIUM BOTULINUM; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPHAGIA; EPISODIC MIGRAINE; EYELID EDEMA; HEADACHE; HUMAN; HYPERHIDROSIS; INJECTION SITE PAIN; JAW PAIN; MIGRAINE; MIGRAINE WITHOUT AURA; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; MYALGIA; NECK MUSCLE; NECK PAIN; PARESTHESIA; PLACEBO EFFECT; PRURITUS; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SHORT SURVEY; SKIN PAIN; TRANSFORMED MIGRAINE; UNITED KINGDOM; WEAKNESS;

EID: 79952638632     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2010.10.0008     Document Type: Short Survey

References (13)

1. Medicines and Healthcare products Regulatory Agency. Botox (Botulinum toxin type A) PL 00426/0074-0105; PL 00426/0118-0025; PL 00426/0119-0007. UKPAR [online]. Available: http://www.mhra.gov.uk/home/groups/par/documents/ websiteresources/con093969.pdf [Accessed 21 January 2011].
2. Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol 2009; 22: 269-76.
3. Olesen J et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6.
4. Management of medication-overuse headache. DTB 2010; 48: 2-6.
5. Silberstein SD et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80.
6. Diener HC et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814-23.
7. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75: 951-7. (Pubitemid 38869604)
8. Joint Formulary Committee. British National Formulary. Edition 60. London: BMJ Group and RPS Publishing, September 2010.
9. Botox 50 units, Botox 100 units, Botox 200 units. Summaries of product characteristics, UK. Allergan Ltd, July 2010.
10. Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet 2010; 376: 1825-6.
11. Aurora SK et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT I trial. Cephalalgia 2010; 30: 793-803.
12. Diener HC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-14.
13. Dodick DW et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-36.